Browse The Full Event Guide to Discover...

  • 18+ expert speakers from toxicology, translation, and clinical development
  • Leading biopharma and academia including BioMarin, Adverum, BridgeBio, Prevail Therapeutics and more
  • Two deep-dive workshop sessions on exploring strategies to reduce vector dosage and minimize AAV safety concerns and assessing the negative AAV safety events and the impact on preclinical testing

Welcome to the 2nd Annual Optimizing Safety Summit

With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be.

In this context, the 2nd Annual Optimizing AAV Safety Summit is returning in 2023, bringing together aav-based therapy leaders across non-clinical development, clinical development, toxicology, biodistribution, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day.

By addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic, analyzing potential integration risks of AAV serotypes, and investigating regulatory approaches to safety packages for submission, this meeting will inform how to streamline AAV safety processes to de-risk delays and shorten timelines to approval.

Join us in Boston to be part of the solution to bringing safer, effective aav therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.


Access the official event guide for more information.

"Very informative and intellectually stimulating with engaged participants and high-quality speakers."


A past Optimizing AAV Safety Summit attendee, bridgebio

2023 World-Class Speaker Faculty Includes:

Genevieve Laforet

Vice President, Clinical Development

Aspa Therapeutics

Kali Stasi

Senior Vice President - Clinical Development


Kei Kishimoto


Selecta Biosciences Inc.

Mansuo Shannon

Chief Scientific Officer

Eli Lilly & Co.

Sharif Tabebordbar

Chief Scientific Officer

Kate Therapeutics

Previously Attending Companies

Copy of LEAPHR_23_GC_Collection

"This summit provided solid scientific discussion of emerging data and topics, as well as an opportunity to talk about the potential implications and considerations for clinical development programs."


A past Optimizing AAV Safety Summit attendee, BridgeBio